Skip to content

Clinicopathological characteristics and pathogenesis of early-onset lung cancer

Clinicopathological characteristics and pathogenesis of early-onset lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113542
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Early onset lung cancer group VS Late onset lung cancer group:none

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Retrospective study Inclusion criteria: 1. Pathologically confirmed primary non-small cell lung cancer; 2. Underwent radical lung cancer resection; 3. Early onset lung cancer group: the age at diagnosis was greater than or equal to 14 years old and less than or equal to 30 years old; 4. Late onset lung cancer control group: older than or equal to 65 years at the time of diagnosis; Prospective study Inclusion criteria: 1. Pathologically confirmed primary non-small cell lung cancer; 2. Did not receive any anti-tumor treatment such as radiotherapy, chemotherapy, targeted therapy, immunotherapy before surgery; 3. No smoking history; 4. Early onset lung cancer group: the age at diagnosis was greater than or equal to 14 years old and less than or equal to 30 years old; 5) Late onset lung cancer control group: older than or equal to 65 years at the time of diagnosis.

Exclusion criteria

Exclusion criteria: Retrospective study Exclusion criteria: 1. Previous history of pulmonary fibrosis, tuberculosis, COPD; 2. Exposure history of asbestos, beryllium, uranium, radon, etc; 3. Concurrent other primary malignancies at diagnosis; 4. Key clinical information missing or patients lost to follow-up. Prospective study Exclusion criteria: 1. Previous history of pulmonary fibrosis, tuberculosis, COPD; 2. Exposure history of asbestos, beryllium, uranium, radon, etc; 3. Concurrent other primary malignancies at diagnosis; 4. The collected samples did not meet the sequencing conditions; 5. Key clinical information missing or patients lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Disease free survival;Frequency of genetic mutations in germ lines and somatic cells associated with hereditary cancer syndrome;

Secondary

MeasureTime frame
Overall survival, OS;Lung Cancer–Specific Survival;

Countries

China

Contacts

Public ContactJian Zhou

West China Hospital of Sichuan University

jian_zhou@wchscu.cn+86 28 8542 2114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026